Skip to main content
VIVS logo

VivoSim Labs, Inc. (VIVS) Stock Price & Analysis

VivoSim Labs, Inc. (VIVS) — MoonshotScore 17/100 (Weak band), calculated Oct 4, 2026. Price $0.1964 (-5.35%), as of the Oct 2, 2026 trading session.

Educational signal · not a buy or sell recommendation · How to read this

$0.1964 −$0.0111 (-5.35%)

VivoSim Labs, Inc. · VIVS

VivoSim Labs, Inc.

Price as of Oct 2, 2026

Key Statistics

17 of 100

MoonshotScore v2 · VivoSim Labs (VIVS)

Weak
Business Quality Poor (4)
Financial Safety Fragile (8)
Valuation Rich (37)
Growth Durability Shrinking (16)
Momentum Falling (8)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Bottom-tier quality, a fragile balance sheet and stalling growth — broad distress, a capital-preservation call, not a value entry. Business Quality: Poor; Financial Safety: Fragile; Valuation: Rich; Growth Durability: Shrinking; Momentum: Falling.

  • quarterly revenue $18,000 (Q1 FY2027, quarter ended Jun 2026)
  • EPS beat 4 of 6

Holding back: weak fundamentals, balance-sheet strain, soft growth, weak price trend

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for VIVS (29 recorded, newest six shown)
RecordedScoreBand
17Weak
17Weak
17Weak
17Weak
17Weak
17Weak

The score was 17 in the stored Oct 3, 2026 snapshot and remains 17 in the current publication computed Oct 4, 2026 (0).

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →

Price & valuation

As of
MeasureValue
Latest provided price$0.1964
Change on the day-5.35%
52-week range$0.1915 – $3.54
Shares traded on the day690.8K

Price & events

Council Score · weighted blend of 2 available disciplines

Council score for VivoSim Labs (VIVS): Split View

35/100 · D

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Growth Durability Negative
Momentum Negative
Business Quality Negative
Financial Safety Negative
Valuation Weak

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Neutral read

Read on: Oct 4, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Negative
ROE Negative
Gross Margin Negative

Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Klarman-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Oct 5, 2026, except a card that shows its own read date.

Watch the VIVS film — every key number, told as a short cinematic story

~2 min · open the film

1 · What is it?

What is VivoSim Labs (VIVS), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. VivoSim Labs, Inc. (VIVS) is the company analyzed here. It employs 15 people and is led by Keith Murphy. In Q1 FY2027 it reported revenue of $18,000 and net income of -$1M.

2 · Latest results

What do the latest results show for VivoSim Labs (VIVS)?

Short answer · as of

The most recent reported quarter, Q1 FY2027, carried revenue of $18,000. Against analyst estimates the company has EPS beat 4 of 6 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q1 FY2027$18,000-$1M-$0.26 (diluted)
Q4 FY2026$40,000-$6M-$2.23 (diluted)
Q3 FY2026$26,000-$3M-$1.84 (diluted)
Q2 FY2026$28,000-$3M-$1.74 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for VivoSim Labs (VIVS)?

Short answer

What is holding it back is weak fundamentals, balance-sheet strain, soft growth, weak price trend. The distress and quality screens read Piotroski F 1. Trailing ratios: current ratio 1.70.

5 · Peer comparison

How does VivoSim Labs compare with its peers?

Short answer

VivoSim Labs's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Theravance Biopharma, Inc. (TBPH) Same industry, near in market value$17.03 Sep 23, 2026$883M95 5-pillar Oct 4, 2026
CorMedix Inc. (CRMD) Same industry, near in market value$7.19 Oct 2, 2026$564M94 5-pillar Oct 4, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$47.15 Oct 2, 2026$872M93 5-pillar Oct 4, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.99 Oct 2, 2026$591M91 5-pillar Oct 4, 2026
MiMedx Group, Inc. (MDXG) Same industry, near in market value$4.59 Oct 2, 2026$669M88 5-pillar Oct 4, 2026
Arbutus Biopharma Corporation (ABUS) Same industry, near in market value$4.45 Oct 2, 2026$879M85 5-pillar Oct 4, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$17.08 Oct 2, 2026$90.6M83 5-pillar Oct 4, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$9.75 Oct 2, 2026$88.2M79 5-pillar Oct 4, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$9.75 Oct 2, 2026$690M77 5-pillar Oct 4, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$4.49 Oct 2, 2026$184M76 5-pillar Oct 4, 2026
Niagen Bioscience Inc (NAGE) Same industry, near in market value$2.79 Oct 2, 2026$222M69 5-pillar Oct 4, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$10.94 Oct 2, 2026$626M68 5-pillar Oct 4, 2026
VivoSim Labs (VIVS) — this page$0.1964—17

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

What has been published about VivoSim Labs (VIVS)?

Read these with our analysis →

Common Questions About VIVS

These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.

What does the MoonshotScore mean for VIVS?

VIVS carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is VIVS a good stock to buy?

Stock Expert AI does not rate VIVS buy, sell or hold. VivoSim Labs, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the VIVS stock price today?

The last price recorded on this page for VivoSim Labs, Inc. (VIVS) is $0.1964, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the key factors to evaluate for VIVS?

VivoSim Labs, Inc. (VIVS) holds a MoonshotScore in the low range. Not financial advice.

How frequently does VIVS data refresh on this page?

VIVS's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven VIVS's recent stock price performance?

VivoSim Labs, Inc. (VIVS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider VIVS overvalued or undervalued right now?

VivoSim Labs, Inc. (VIVS) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research VIVS before investing?

Before investing in VivoSim Labs, Inc. (VIVS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding VIVS to a portfolio?

No dossier-level strength is on record for VivoSim Labs, Inc. (VIVS) yet — start from the MoonshotScore factor breakdown and the Financials tab on this page. Weigh rewards against risks and diversify. Not financial advice.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources — records for every figure on this page (15 figures)

The 15 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.

"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.

FMP — 7 facts from Financial Modeling Prep endpoint families

FMP facts used on this page
Fact IDFactValue as shownAs ofTierSource
px.lastLatest provided price$0.1964FMPFinancial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T09:24:51.734Z.
px.changeChange on the day-5.35%FMPFinancial Modeling Prep (FMP) · quote
px.change_absChange on the day, in dollars−$0.0111FMPFinancial Modeling Prep (FMP) · quote
fin.q_revenueRevenue, Q1 FY2027$18,000FMPFinancial Modeling Prep (FMP) · income statement (quarterly)
px.volumeShares traded on the day690.8KFMPFinancial Modeling Prep (FMP) · quote
fin.q_incomeNet income, Q1 FY2027-$1MFMPFinancial Modeling Prep (FMP) · income statement (quarterly)
fin.q_tableQuarterly income statement4 quarters through Q1 FY2027FMPFinancial Modeling Prep (FMP) · income statement (quarterly), as filed

UNRECORDED — 6 facts from stored observations whose source was not recorded

UNRECORDED facts used on this page
Fact IDFactValue as shownAs ofTierSource
earn.historyReported versus estimated, recent quartersEPS beat 4 of 6UNRECORDEDStored earnings-history observation — Captured 2026-09-15 · Expired observation
px.range5252-week range$0.1915 – $3.54UNRECORDEDStored company-profile observation — Captured 2026-10-02
id.employeesEmployees15UNRECORDEDStored company-profile observation — Captured 2026-10-02
id.ceoChief executiveKeith MurphyUNRECORDEDStored company-profile observation — Captured 2026-10-02
fin.scoresDistress and quality screensPiotroski F 1UNRECORDEDStored financial-scores observation — Captured 2026-10-03 · Expired observation
fin.ratiosReturn and yield ratios (trailing twelve months)current ratio 1.70—UNRECORDEDStored key metrics — Date unknown

OURS — 2 facts from Stock Expert AI's own score and rank

OURS facts used on this page
Fact IDFactValue as shownAs ofTierSource
ours.moonshotMoonshotScore v217 of 100 · Weak · pillars 4 / 8 / 37 / 16 / 8OURSStock Expert AI MoonshotScore v2 engine
ours.moonshot_changeMoonshotScore movement17 (stored snapshot Oct 3, 2026) → 17 (current publication computed Oct 4, 2026) (0)OURSStock Expert AI current score publication and immutable score snapshots
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.